Please wait while the formulary information is being retrieved.
Drug overview for AVMAPKI (avutometinib potassium):
Generic name: AVUTOMETINIB POTASSIUM
Drug class: Antineoplastic - MEK1 and MEK2 Kinase Inhibitors
Therapeutic class: Antineoplastics
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: AVUTOMETINIB POTASSIUM
Drug class: Antineoplastic - MEK1 and MEK2 Kinase Inhibitors
Therapeutic class: Antineoplastics
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
AVMAPKI 0.8 MG CAPSULE
The following indications for AVMAPKI (avutometinib potassium) have been approved by the FDA:
Indications:
Low-grade serous ovarian cancer with KRAS mutation
Professional Synonyms:
Low grade serous adenocarcinoma of ovary with KRAS mutation
Indications:
Low-grade serous ovarian cancer with KRAS mutation
Professional Synonyms:
Low grade serous adenocarcinoma of ovary with KRAS mutation
The following dosing information is available for AVMAPKI (avutometinib potassium):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| AVMAPKI 0.8 MG CAPSULE | Maintenance | Adults take 4 capsules (3.2 mg) by oral route twice weekly on days 1 and 4 of weeks 1 to 3 of each 4-week cycle; per protocol with defactinib |
No generic dosing information available.
The following drug interaction information is available for AVMAPKI (avutometinib potassium):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for AVMAPKI (avutometinib potassium):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Lactation |
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Pregnancy |
There are 0 moderate contraindications.
The following adverse reaction information is available for AVMAPKI (avutometinib potassium):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 4 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Hydronephrosis Intestinal obstruction Pyelonephritis Sepsis |
| Rare/Very Rare |
|---|
| None. |
There are 46 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abnormal hepatic function tests Acute abdominal pain Anemia Constipation Cough Diarrhea Dry skin Dyspepsia Dyspnea Edema Fatigue Hyperbilirubinemia Hypertriglyceridemia Increased creatine kinase level Lymphopenia Musculoskeletal pain Nausea Neutropenic disorder Pruritus of skin Skin rash Stomatitis Thrombocytopenic disorder Urinary tract infection Visual changes Vomiting |
Alopecia Anorexia Dizziness Dry eye Dysgeusia Headache disorder Hemorrhage Hypertension Hypoalbuminemia Hypokalemia Paronychia Periorbital edema Peripheral neuropathy Proteinuria Retinal detachment Skin photosensitivity Upper respiratory infection Venous thrombosis Vitreous floater Weight loss Xerostomia |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for AVMAPKI (avutometinib potassium):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for AVMAPKI (avutometinib potassium):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for AVMAPKI (avutometinib potassium)'s list of indications:
| Low-grade serous ovarian cancer with KRAS mutation | |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.3 | Malignant neoplasm of bilateral ovaries |
| C56.9 | Malignant neoplasm of unspecified ovary |
Formulary Reference Tool